Cerebroprotein Hydrolysate 215.2mg/10ml Injection

Cerebroprotein Hydrolysate 215.2mg/10ml Injection is a specialized neurotrophic and neuroprotective therapeutic agent derived from highly purified porcine brain proteins. This unique pharmaceutical preparation consists of a complex mixture of low-molecular-weight peptides and free amino acids that are capable of crossing the blood-brain barrier to exert direct effects on the central nervous system. The primary mechanism of action of Cerebroprotein Hydrolysate 215.2mg/10ml Injection involves its ability to mimic the activity of natural neurotrophic factors, such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). By promoting neuronal survival, stimulating synaptogenesis, and enhancing the metabolic activity of brain cells, this powerful injection facilitates the repair of damaged neural pathways and protects healthy neurons from oxidative stress and excitotoxicity. Discover the ultimate clinical benefits of this medication in restoring cognitive and motor functions after acute or chronic neurological insults, ensuring a more effective recovery process for patients facing debilitating brain conditions.

Indications / Uses of Cerebroprotein Hydrolysate 215.2mg/10ml Injection

Cerebroprotein Hydrolysate 215.2mg/10ml Injection is commonly prescribed for:

• Post-Stroke Recovery: This medication is a cornerstone in the rehabilitation phase of ischemic and hemorrhagic strokes. Cerebroprotein Hydrolysate 215.2mg/10ml Injection helps in the functional recovery of motor skills and speech by protecting the penumbra—the area of brain tissue surrounding the primary stroke site that is at risk of further damage but still salvageable.
• Traumatic Brain Injury (TBI): Patients suffering from head injuries benefit from the neuroprotective properties of the drug, which help reduce secondary injury cascades like brain edema and metabolic failure, thereby improving long-term neurological outcomes.
• Dementia and Alzheimer’s Disease: It is used as supportive therapy to manage symptoms of cognitive decline. By improving the metabolic rate of neurons, Cerebroprotein Hydrolysate 215.2mg/10ml Injection can enhance memory, attention, and executive functions in patients with vascular or neurodegenerative dementia.
• Craniocerebral Surgeries: Surgeons may prescribe this injection post-operatively to support the brain’s healing process and minimize the cognitive deficits that can sometimes occur following invasive neurological procedures.
• Neurovascular Complications: It is indicated for various organic, metabolic, and neurodegenerative disorders of the brain where there is a clear deficit in neuronal communication or a need for metabolic stimulation.

Key Features

• Direct Neurotrophic Action: Unlike general stimulants, Cerebroprotein Hydrolysate 215.2mg/10ml Injection acts specifically on neuronal survival and repair pathways, providing the brain with the essential building blocks for cellular restoration.
• High Blood-Brain Barrier Penetration: The low molecular weight of the constituent peptides ensures that the active components efficiently reach the target sites within the central nervous system after systemic administration.
• Synergistic Peptide Complex: The solution contains a balanced ratio of amino acids and biologically active peptides that work in harmony to improve brain metabolism and protect against hypoxic damage.
• Versatile Administration: Available as a 10ml injection, it can be administered through various routes including slow intravenous (IV) infusion or intramuscular (IM) injection, depending on the severity of the clinical situation.
• Clinically Proven Safety: With a long history of use in neurology, Cerebroprotein Hydrolysate 215.2mg/10ml Injection is known for its high tolerability and low incidence of systemic adverse effects, making it suitable for elderly and fragile patients.

Storage for Cerebroprotein Hydrolysate 215.2mg/10ml Injection

Proper storage is vital for maintaining the biochemical activity of the delicate peptides contained within Cerebroprotein Hydrolysate 215.2mg/10ml Injection. The ampoules should be stored at a temperature not exceeding 25°C (77°F). Exposure to extreme heat or freezing conditions must be strictly avoided, as temperature fluctuations can cause the denaturation of the active protein fragments. It is equally important to protect the injection from direct sunlight and artificial UV light by keeping the vials in their original outer carton until the moment of use. Once an ampoule is opened, the solution must be used immediately; any leftover portion should be discarded, as the product does not contain preservatives and is susceptible to microbial contamination. Always ensure that the medication is stored in a secure location, out of the reach and sight of children and pets, to prevent accidental exposure.

Important Note on Cerebroprotein Hydrolysate 215.2mg/10ml Injection

The administration of Cerebroprotein Hydrolysate 215.2mg/10ml Injection should only be performed under the direct supervision of a qualified medical professional, typically a neurologist or a physician specialized in critical care. The dosage and duration of treatment are highly individualized, based on the patient’s age, the specific neurological condition being treated, and the severity of the symptoms. For acute conditions like stroke, the injection is often given as a daily intravenous infusion over a period of 10 to 20 days. It is essential to monitor the rate of infusion; rapid administration may cause a temporary sensation of heat or sweating.

Patients must be screened for contraindications before starting Cerebroprotein Hydrolysate 215.2mg/10ml Injection. It is strictly contraindicated in individuals with a known hypersensitivity to any of its components or to porcine proteins. Furthermore, patients suffering from severe renal impairment or those with a history of status epilepticus or frequent grand mal seizures should not use this medication, as it may potentially lower the seizure threshold. While the drug is generally well-tolerated, some patients may experience mild side effects such as dizziness, headache, nausea, or a slight increase in body temperature. In rare instances, allergic reactions or skin rashes may occur.

It is important to inform your healthcare provider about all other medications you are currently taking, particularly antidepressants or MAO inhibitors, as potential pharmacological interactions should be assessed. The safety of Cerebroprotein Hydrolysate 215.2mg/10ml Injection during pregnancy and lactation has not been fully established; therefore, its use in pregnant or breastfeeding women should only be considered if the potential benefits clearly outweigh the risks to the fetus or infant. This medication is most effective when integrated into a comprehensive rehabilitation program that includes physical therapy, speech therapy, and cognitive exercises. Regular neurological assessments are recommended to monitor progress and adjust the treatment plan accordingly. If any signs of a severe allergic reaction occur, such as swelling of the lips or tongue, or difficulty breathing, immediate emergency medical attention is required. By adhering to the prescribed protocol, patients can maximize the effective relief provided by this powerful neuroprotective treatment.